These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25960935)

  • 1. Molecular mimicry of MAGE-A6 and
    Vujanovic L; Shi J; Kirkwood JM; Storkus WJ; Butterfield LH
    Oncoimmunology; 2014; 3(8):e954501. PubMed ID: 25960935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.
    Vujanovic L; Mandic M; Olson WC; Kirkwood JM; Storkus WJ
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6796-806. PubMed ID: 18006782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
    Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
    Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
    [No Abstract]   [Full Text] [Related]  

  • 7. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
    Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
    J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
    Eifuku R; Takenoyama M; Yoshino I; Imahayashi S; So T; Yasuda M; Sugaya M; Yasumoto K
    Int J Clin Oncol; 2001 Feb; 6(1):34-9. PubMed ID: 11706525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
    Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
    J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
    Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
    J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cell Cross-Reactivity between a Highly Immunogenic EBV Epitope and a Self-Peptide Naturally Presented by HLA-B*18:01+ Cells.
    Rist MJ; Hibbert KM; Croft NP; Smith C; Neller MA; Burrows JM; Miles JJ; Purcell AW; Rossjohn J; Gras S; Burrows SR
    J Immunol; 2015 May; 194(10):4668-75. PubMed ID: 25855358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
    Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U
    Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of Artificial Immunogens Containing Melanoma-associated T-cell Epitopes.
    Borobova EA; Antonets DV; Starostina EV; Karpenko LI; Ilyichev AA; Bazhan SI
    Curr Gene Ther; 2018; 18(6):375-385. PubMed ID: 30421674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.
    Britten CM; Meyer RG; Kreer T; Drexler I; Wölfel T; Herr W
    J Immunol Methods; 2002 Jan; 259(1-2):95-110. PubMed ID: 11730845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.